Capital One Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $7
Portfolio Pulse from richadhand@benzinga.com
Capital One analyst Tim Chiang has initiated coverage on Jasper Therapeutics (NASDAQ:JSPR) with an Overweight rating and a price target of $7.
August 11, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jasper Therapeutics receives an Overweight rating from Capital One with a price target of $7.
The Overweight rating from Capital One indicates a positive outlook for Jasper Therapeutics. The price target of $7 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100